Topic
Deals & IPOs
Biotech and health IPOs, S-1 filings, private rounds, the J.P. Morgan Healthcare Conference week, and AI companies moving into life sciences. Read from SEC filings, never investment advice.
- AI at Work
Reading Iambic's S-1: An AI Drug IPO, Risk Factors First
One drug in early clinical testing, a $245 million accumulated deficit, and a platform the company itself calls unproven. The prospectus is more candid than the headlines.
- AI at Work
Anthropic Moves Into Biology: What Is Announced vs Shown
Four launches in three months. One produced a preprint about an enzyme system whose function is still unknown. The rest are access rules, pilots and promises.
GLP-1 & Metabolic HealthBiological Age & ClocksHeart & LipidsMuscle & Body CompositionAI Models & BenchmarksAI at Work & GovernanceWearables & Body RhythmsBrain & MindReading the EvidenceSpacePlanet & EnergyEconomyPipelines & TrialsDeals & IPOsCorrections & Retractions
Get Facts First, every Sunday
One email a week: the 5 facts that mattered in AI, health and longevity, each checked against the original source. No spam. Unsubscribe in one click.
By subscribing you agree to receive the newsletter. See the privacy policy.